Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF

被引:107
作者
O'Brien, RJ [1 ]
Squire, IB [1 ]
Demme, B [1 ]
Davies, JE [1 ]
Ng, LL [1 ]
机构
[1] Univ Leicester, Leicester Royal Infirm, Dept Med & Therapeut, Leicester LE2 7LX, Leics, England
关键词
heart failure; natriuretic peptides; prognosis;
D O I
10.1016/S1388-9842(03)00098-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Circulating natriuretic peptide levels provide prognostic information following acute coronary syndromes and in chronic heart failure. Little evidence exists of their utility following hospitalisation with acute left ventricular failure (LVF). Aims: To examine the relative prognostic value of admission and pre-discharge plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) following hospitalisation with acute heart failure. Methods: NT-proBNP was measured at admission in 96 patients hospitalised with acute LVF In a subset of 34 patients, NT-proBNP was also measured prior to discharge. Multivariate analysis was performed of the clinical and serological predictors of a combined primary endpoint of death or heart failure (hospitalisation or as an outpatient). Results: During follow up (median 350 days, range 2-762), 37 (38.5%) patients died (n=16, 16.7%), or experienced at least 1 heart failure event (n=21, 21.9%). For the entire cohort of 96 patients, only a prior history of heart failure was associated with the primary endpoint (OR 3.5 [1.10-11.08], P=0.034). Admission plasma NT-proBNP was not predictive (OR 1.84 [0.75-4.51], P=0.185). In the 34 patients for whom both admission and pre-discharge NT-proBNP was available, 19 (55.9%) died (n=8, 23.5%) or experienced heart failure (n=11, 32.4%). Only pre-discharge plasma NT-proBNP (OR 15.30 [95% CI: 1.4-168.9], P=0.026) was independently predictive of the composite endpoint. The area under the receiver-operator-characteristic (AUC ROC) curve for pre-discharge NT-proBNP was superior to that for admission NT-proBNP for prediction of death or heart failure (AUC ROC 0.87 cf 0.70), for death (0.79 cf 0.66), LVF hospitalisation (0.78 cf 0.70) or heart failure as an outpatient (0.71 cf 0.61). Conclusions: Plasma NT-proBNP measured pre-discharge provides useful prognostic information following hospitalisation with acute LVF. (C) 2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:499 / 506
页数:8
相关论文
共 28 条
[1]   Predictors of prognosis in patients with stable mild to moderate heart failure [J].
Bettencourt, P ;
Ferreira, A ;
Dias, P ;
Pimenta, J ;
Frioes, F ;
Martins, L ;
Cerqueira-Gomes, M .
JOURNAL OF CARDIAC FAILURE, 2000, 6 (04) :306-313
[2]   Hospitalization of patients with heart failure - A population-based study [J].
Cowie, MR ;
Fox, KF ;
Wood, DA ;
Metcalfe, C ;
Thompson, SG ;
Coats, AJS ;
Poole-Wilson, PA ;
Sutton, GC .
EUROPEAN HEART JOURNAL, 2002, 23 (11) :877-885
[3]   The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Bentley, JH ;
Omland, T ;
Sabatine, MS ;
McCabe, CH ;
Hall, C ;
Cannon, CP ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1014-1021
[4]   THE USE OF ACRIDINIUM ESTER-LABELED STREPTAVIDIN IN IMMUNOASSAYS [J].
HART, RC ;
TAAFFE, LR .
JOURNAL OF IMMUNOLOGICAL METHODS, 1987, 101 (01) :91-96
[5]   Primary care physicians: champions of or an impediment to optimal care of the patient with heart failure? [J].
Hobbs, FDR .
EUROPEAN JOURNAL OF HEART FAILURE, 1999, 1 (01) :11-15
[6]   An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction [J].
Hughes, D ;
Talwar, S ;
Squire, IB ;
Davies, JE ;
Ng, LL .
CLINICAL SCIENCE, 1999, 96 (04) :373-380
[7]   Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment [J].
Hunt, PJ ;
Richards, AM ;
Nicholls, MG ;
Yandle, TG ;
Doughty, RN ;
Espiner, EA .
CLINICAL ENDOCRINOLOGY, 1997, 47 (03) :287-296
[8]   Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation [J].
Inoue, S ;
Murakami, Y ;
Sano, K ;
Katoh, H ;
Shimada, T .
JOURNAL OF CARDIAC FAILURE, 2000, 6 (02) :92-96
[9]  
Karl J, 1999, SCAND J CLIN LAB INV, V59, P177
[10]   Evidence of improving prognosis in heart failure - Trends in case fatality in 66 547 patients hospitalized between 1986 and 1995 [J].
MacIntyre, K ;
Capewell, S ;
Stewart, S ;
Chalmers, JWT ;
Boyd, J ;
Finlayson, A ;
Redpath, A ;
Pell, JP ;
McMurray, JJV .
CIRCULATION, 2000, 102 (10) :1126-1131